{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:06:04Z","timestamp":1780376764871,"version":"3.54.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Idiopathic inflammatory myopathies (IIM) are rare disorders characterised by the presence of skeletal muscle inflammation, with interstitial lung disease (ILD) being the most frequent pulmonary manifestation. The spectrum of clinical presentations of myositis related ILD (M-ILD) encompasses a chronic process to a rapidly progressive ILD (RP-ILD); which is associated with a high mortality rate. The most effective treatments remain controversial and poses a unique challenge to both rheumatologists and respiratory physicians to manage. Given the rare heterogenous nature of M-ILD, there is a paucity of data to guide treatment. The cornerstone of existing treatments encompasses combinations of immunosuppressive therapies, as well as non-pharmacological therapies. In this review, we aim to summarize the current pharmacological therapies (including its dosing regimens and side effects profiles) and non-pharmacological therapies. Based on the existing literature to date, we propose a treatment algorithm for both chronic M-ILD and RP-ILD.<\/jats:p>","DOI":"10.1007\/s00296-023-05336-z","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T13:02:05Z","timestamp":1682946125000},"page":"1209-1220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["\u201cManagement of myositis associated interstitial lung disease\u201d"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4992-3378","authenticated-orcid":false,"given":"Lorraine","family":"Thong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3761-0772","authenticated-orcid":false,"given":"Liam J.","family":"Chawke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-7724","authenticated-orcid":false,"given":"Grainne","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-2938","authenticated-orcid":false,"given":"Michael T.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"issue":"5","key":"5336_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","volume":"20","author":"CA Mecoli","year":"2018","unstructured":"Mecoli CA, Christopher-Stine L (2018) Management of interstitial lung disease in patients with myositis specific autoantibodies. Curr Rheumatol Rep 20(5):27","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"5336_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","volume":"54","author":"A Meyer","year":"2015","unstructured":"Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 54(1):50\u201363","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"5336_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292(7):344\u2013347","journal-title":"N Engl J Med"},{"issue":"8","key":"5336_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292(8):403\u2013407","journal-title":"N Engl J Med"},{"issue":"12","key":"5336_CR5","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M et al (2017) 2017 European league against Rheumatism\/American College of Rheumatology classification criteria for adult and Juvenile Idiopathic Inflammatory Myopathies and their major subgroups. Arthritis Rheum (Hoboken, NJ) 69(12):2271\u20132282","journal-title":"Arthritis Rheum (Hoboken, NJ)"},{"issue":"1","key":"5336_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","volume":"51","author":"KY Sun","year":"2021","unstructured":"Sun KY, Fan Y, Wang YX, Zhong YJ, Wang GF (2021) Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020. Semin Arthritis Rheum 51(1):175\u2013191","journal-title":"Semin Arthritis Rheum"},{"key":"5336_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40064-015-1013-8","volume":"4","author":"S Ikeda","year":"2015","unstructured":"Ikeda S, Arita M, Misaki K et al (2015) Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Springerplus 4:240","journal-title":"Springerplus"},{"issue":"5","key":"5336_CR8","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","volume":"61","author":"AGS Oldroyd","year":"2022","unstructured":"Oldroyd AGS, Lilleker JB, Amin T et al (2022) British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 61(5):1760\u20131768","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"5336_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409\u20131417","journal-title":"Rheumatol Int"},{"issue":"2","key":"5336_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-180308","volume":"5","author":"J Schmidt","year":"2018","unstructured":"Schmidt J (2018) Current classification and management of inflammatory myopathies. J Neuromuscular Dis 5(2):109\u2013129","journal-title":"J Neuromuscular Dis"},{"key":"5336_CR11","first-page":"290","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nature reviews. Rheumatology 14:290","journal-title":"Rheumatology"},{"key":"5336_CR12","doi-asserted-by":"publisher","first-page":"1759720","DOI":"10.1177\/1759720X20975907","volume":"12","author":"A Lackner","year":"2020","unstructured":"Lackner A, Tiefenthaler V, Mirzayeva J et al (2020) The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study. Ther Adv Musculoskelet Dis 12:1759720\u201320975907","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"5336_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T (2016) Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25(8):925\u2013933","journal-title":"Lupus"},{"issue":"1","key":"5336_CR14","doi-asserted-by":"publisher","first-page":"105048","DOI":"10.1016\/j.jbspin.2020.06.021","volume":"88","author":"A Leurs","year":"2021","unstructured":"Leurs A, Dubucquoi S, Machuron F et al (2021) Extended myositis-specific and -associated antibodies profile in systemic sclerosis: a cross-sectional study. Joint Bone Spine 88(1):105048","journal-title":"Joint Bone Spine"},{"issue":"7","key":"5336_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","volume":"5","author":"S Sato","year":"2018","unstructured":"Sato S, Masui K, Nishina N et al (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford) 5(7):1212","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"5336_CR16","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","volume":"150","author":"J Morisset","year":"2016","unstructured":"Morisset J, Johnson C, Rich E, Collard HR, Lee JS (2016) Management of myositis-related interstitial lung disease. Chest 150(5):1118\u20131128","journal-title":"Chest"},{"issue":"3","key":"5336_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","volume":"84","author":"MP Debray","year":"2015","unstructured":"Debray MP, Borie R, Revel MP et al (2015) Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur J Radiol 84(3):516\u2013523","journal-title":"Eur J Radiol"},{"issue":"1","key":"5336_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12890-021-01399-5","volume":"21","author":"X Zhan","year":"2021","unstructured":"Zhan X, Yan W, Wang Y et al (2021) Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. BMC Pulm Med 21(1):57","journal-title":"BMC Pulm Med"},{"issue":"4","key":"5336_CR19","first-page":"1","volume":"7","author":"A Selva-O'Callaghan","year":"2021","unstructured":"Selva-O\u2019Callaghan A, Romero-Bueno F, Trallero-Aragu\u00e1s E et al (2021) Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease. Curr Treatm Opt Rheum 7(4):1\u201315","journal-title":"Curr Treatm Opt Rheum"},{"key":"5336_CR20","doi-asserted-by":"publisher","first-page":"1759720","DOI":"10.1177\/1759720X211032457","volume":"13","author":"M Kuwana","year":"2021","unstructured":"Kuwana M, Gil-Vila A, Selva-O\u2019Callaghan A (2021) Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 13:1759720\u2013211032457","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"5336_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1055\/s-0034-1371528","volume":"35","author":"RW Hallowell","year":"2014","unstructured":"Hallowell RW, Ascherman DP, Danoff SK (2014) Pulmonary manifestations of polymyositis\/dermatomyositis. Semi Res Critic Care Med 35(2):239\u2013248","journal-title":"Semi Res Critic Care Med"},{"issue":"2","key":"5336_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"WD Travis","year":"2002","unstructured":"Travis WD, King TE, Bateman ED, Lynch DA, Capron F, Center D, Colby TV, Cordier JF, DuBois RM, Galvin J, Grenier P (2002) American Thoracic Society\/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Res Critic Care Med 165(2):277\u2013304","journal-title":"Am J Res Critic Care Med"},{"issue":"1","key":"5336_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.chest.2020.01.033","volume":"158","author":"R Jablonski","year":"2020","unstructured":"Jablonski R, Bhorade S, Strek ME, Dematte J (2020) Recognition and management of myositis-associated rapidly progressive interstitial lung disease. Chest 158(1):252\u2013263","journal-title":"Chest"},{"key":"5336_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fmed.2020.00363","volume":"7","author":"Y Li","year":"2020","unstructured":"Li Y, Gao X, Li Y et al (2020) Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: a series of 474 patients. Front Med (Lausanne) 7:363","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"5336_CR25","doi-asserted-by":"publisher","first-page":"33226","DOI":"10.1038\/srep33226","volume":"6","author":"T Li","year":"2016","unstructured":"Li T, Guo L, Chen Z et al (2016) Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 6(1):33226","journal-title":"Sci Rep"},{"issue":"1","key":"5336_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65(1):25\u201334","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"5336_CR27","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/acr.21728","volume":"64","author":"H Cao","year":"2012","unstructured":"Cao H, Pan M, Kang Y et al (2012) Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res 64(10):1602\u20131610","journal-title":"Arthritis Care Res"},{"issue":"3","key":"5336_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/acr.24646","volume":"74","author":"H Furuya","year":"2021","unstructured":"Furuya H, Nakajima M, Ikeda K et al (2021) Prognosis and treatment of myositis-associated severe interstitial lung disease: a descriptive study using a nation-wide inpatient database in Japan. Arthrit Care Res 74(3):478\u2013483","journal-title":"Arthrit Care Res"},{"issue":"7","key":"5336_CR29","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Hara M et al (2010) Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49(7):1354\u20131360","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5336_CR30","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","volume":"105","author":"K Tanizawa","year":"2011","unstructured":"Tanizawa K, Handa T, Nakashima R et al (2011) HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 105(9):1380\u20131387","journal-title":"Respir Med"},{"issue":"1","key":"5336_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/thx.2006.069237","volume":"63","author":"I Tillie-Leblond","year":"2008","unstructured":"Tillie-Leblond I, Wislez M, Valeyre D et al (2008) Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 63(1):53\u201359","journal-title":"Thorax"},{"issue":"6","key":"5336_CR32","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138(6):1464\u20131474","journal-title":"Chest"},{"issue":"2","key":"5336_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","volume":"18","author":"T Barba","year":"2018","unstructured":"Barba T, Fort R, Cottin V et al (2018) Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev 18(2):113\u2013122","journal-title":"Autoimmun Rev"},{"issue":"2","key":"5336_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.55563\/clinexprheumatol\/brvl1v","volume":"40","author":"R Hallowell","year":"2021","unstructured":"Hallowell R, Paik JJ (2021) Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clin Exp Rheum 40(2):373\u2013383","journal-title":"Clin Exp Rheum"},{"issue":"6","key":"5336_CR35","doi-asserted-by":"publisher","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","volume":"9","author":"T Fujisawa","year":"2014","unstructured":"Fujisawa T, Hozumi H, Kono M et al (2014) Prognostic factors for myositis-associated interstitial lung disease. PLoS ONE 9(6):e98824","journal-title":"PLoS ONE"},{"issue":"6","key":"5336_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14397595.2018.1467257","volume":"28","author":"H Sasaki","year":"2018","unstructured":"Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28(6):913\u2013921","journal-title":"Mod Rheumatol"},{"issue":"6","key":"5336_CR37","first-page":"1064","volume":"35","author":"A Berezne","year":"2008","unstructured":"Berezne A, Ranque B, Valeyre D et al (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheum 35(6):1064\u20131072","journal-title":"J Rheum"},{"issue":"4","key":"5336_CR38","first-page":"613","volume":"25","author":"C Paone","year":"2007","unstructured":"Paone C, Chiarolanza I, Cuomo G et al (2007) Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1\u00a0year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 25(4):613\u2013616","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5336_CR39","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","volume":"156","author":"JA Huapaya","year":"2019","unstructured":"Huapaya JA, Silhan L, Pinal-Fernandez I et al (2019) Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest 156(5):896\u2013906","journal-title":"Chest"},{"key":"5336_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","volume":"121","author":"JM Oldham","year":"2016","unstructured":"Oldham JM, Lee C, Valenzi E et al (2016) Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med 121:117\u2013122","journal-title":"Respir Med"},{"issue":"9","key":"5336_CR41","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"5","key":"5336_CR42","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640\u2013646","journal-title":"J Rheumatol"},{"issue":"5","key":"5336_CR43","first-page":"1594","volume":"161","author":"SD Lok","year":"2021","unstructured":"Lok SD, Wong AW, Khor YH, Ryerson CJ, Johannson KA (2021) Malignancy risk associated with mycophenolate mofetil or azathioprine in patients with fibrotic interstitial lung disease. Chest 161(5):1594","journal-title":"Chest"},{"issue":"3","key":"5336_CR44","first-page":"215","volume":"32","author":"DB Fitzgerald","year":"2015","unstructured":"Fitzgerald DB, Moloney F, Twomey M et al (2015) Efficacy and safety of rituximab in connective tissue disease related interstitial lung disease. Sarcoid Vasculitis Diff Lung Dis Off J WASOG 32(3):215\u2013221","journal-title":"Sarcoid Vasculitis Diff Lung Dis Off J WASOG"},{"issue":"8","key":"5336_CR45","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3899\/jrheum.150844","volume":"43","author":"J Bauhammer","year":"2016","unstructured":"Bauhammer J, Blank N, Max R et al (2016) Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol 43(8):1566\u20131574","journal-title":"J Rheumatol"},{"issue":"11","key":"5336_CR46","doi-asserted-by":"publisher","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","volume":"10","author":"Y Allenbach","year":"2015","unstructured":"Allenbach Y, Guiguet M, Rigolet A et al (2015) Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label. Phase II Trial PLoS One 10(11):e0133702","journal-title":"Phase II Trial PLoS One"},{"issue":"6","key":"5336_CR47","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.170541","volume":"45","author":"TJ Doyle","year":"2018","unstructured":"Doyle TJ, Dhillon N, Madan R et al (2018) Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. J Rheumatol 45(6):841\u2013850","journal-title":"J Rheumatol"},{"issue":"5","key":"5336_CR48","first-page":"181","volume":"34","author":"G Lepri","year":"2016","unstructured":"Lepri G, Avouac J, Airo P et al (2016) Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheum 34(5):181\u2013185","journal-title":"Clin Exp Rheum"},{"issue":"1","key":"5336_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P et al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11(1):45\u201354","journal-title":"Lancet Respir Med"},{"issue":"11","key":"5336_CR50","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3899\/jrheum.190505","volume":"47","author":"V Langlois","year":"2020","unstructured":"Langlois V, Gillibert A, Uzunhan Y et al (2020) Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study. J Rheum 47(11):1678\u20131686","journal-title":"J Rheum"},{"issue":"1","key":"5336_CR51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki Y, Yamada H, Yamasaki M et al (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology (Oxford) 46(1):124\u2013130","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5336_CR52","first-page":"010908","volume":"1","author":"H Barnes","year":"2018","unstructured":"Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN (2018) Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev 1(1):010908","journal-title":"Cochrane Database Syst Rev"},{"issue":"9166","key":"5336_CR53","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","volume":"353","author":"CV Oddis","year":"1999","unstructured":"Oddis CV, Sciurba FC, Elmagd KA, Starzl TE (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet (London, England) 353(9166):1762\u20131763","journal-title":"Lancet (London, England)"},{"issue":"8","key":"5336_CR54","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/art.21240","volume":"52","author":"MR Wilkes","year":"2005","unstructured":"Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV (2005) Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 52(8):2439\u20132446","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5336_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","volume":"54","author":"T Kurita","year":"2015","unstructured":"Kurita T, Yasuda S, Oba K et al (2015) The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 54(1):39\u201344","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"5336_CR56","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","volume":"34","author":"Y Ge","year":"2015","unstructured":"Ge Y, Zhou H, Shi J et al (2015) The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review. Clin Rheumatol 34(12):2097\u20132103","journal-title":"Clin Rheumatol"},{"issue":"1","key":"5336_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","volume":"27","author":"SS Farouk","year":"2020","unstructured":"Farouk SS, Rein JL (2020) The many faces of calcineurin inhibitor toxicity-what the FK? Adv Chronic Kidney Dis 27(1):56\u201366","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"5336_CR58","first-page":"1045","volume":"14","author":"WB Gruhn","year":"1987","unstructured":"Gruhn WB, Diaz-Buxo JA (1987) Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis\/polymyositis. J Rheumatol 14(5):1045\u20131047","journal-title":"J Rheumatol"},{"issue":"1","key":"5336_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","volume":"36","author":"DJ Go","year":"2016","unstructured":"Go DJ, Park JK, Kang EH et al (2016) Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int 36(1):125\u2013131","journal-title":"Rheumatol Int"},{"issue":"8","key":"5336_CR60","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10067-011-1713-6","volume":"30","author":"T Kotani","year":"2011","unstructured":"Kotani T, Takeuchi T, Makino S et al (2011) Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute\/subacute interstitial pneumonia. Clin Rheumatol 30(8):1021\u20131028","journal-title":"Clin Rheumatol"},{"issue":"4","key":"5336_CR61","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/resp.13978","volume":"26","author":"T Fujisawa","year":"2021","unstructured":"Fujisawa T, Hozumi H, Kamiya Y et al (2021) Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: A randomized, open-label trial. Respirology (Carlton, Vic) 26(4):370\u2013377","journal-title":"Respirology (Carlton, Vic)"},{"issue":"6","key":"5336_CR62","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.42075","volume":"74","author":"EL Matteson","year":"2022","unstructured":"Matteson EL, Kelly C, Distler JHW et al (2022) Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. Arthritis Rheum (Hoboken, NJ) 74(6):1039\u20131047","journal-title":"Arthritis Rheum (Hoboken, NJ)"},{"key":"5336_CR63","doi-asserted-by":"publisher","first-page":"33226","DOI":"10.1038\/srep33226","volume":"6","author":"T Li","year":"2016","unstructured":"Li T, Guo L, Chen Z et al (2016) Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 6:33226","journal-title":"Sci Rep"},{"key":"5336_CR64","unstructured":"Genentech USA (2023) Safety & Tolerability Esbriet\u00ae (pirfenidone) offers established safety built on multiple clinical studies. https:\/\/www.esbriethcp.com\/side-effects\/safety-tolerability.html. Accessed 3 Mar 2023"},{"issue":"12","key":"5336_CR65","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler JHW, Gy\u00f6rfi AH, Ramanujam M, Whitfield ML, K\u00f6nigshoff M, Lafyatis R (2019) Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 15(12):705\u2013730","journal-title":"Nat Rev Rheumatol"},{"key":"5336_CR66","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ebiom.2019.10.050","volume":"50","author":"AM Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold AM, Weigt SS, Saggar R et al (2019) Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine 50:379\u2013386","journal-title":"EBioMedicine"},{"issue":"12","key":"5336_CR67","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y et al (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheum (Oxford) 53(12):2196\u20132203","journal-title":"Rheum (Oxford)"},{"issue":"8S","key":"5336_CR68","first-page":"S574","volume":"27","author":"M Kato","year":"2019","unstructured":"Kato M, Ikeda K, Kageyama T et al (2019) Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis. J Clin Rheum Pract Rep Rheum Musculoskeletal Dis 27(8S):S574\u2013S577","journal-title":"J Clin Rheum Pract Rep Rheum Musculoskeletal Dis"},{"issue":"12","key":"5336_CR69","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y et al (2018) Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57(12):2114\u20132119","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5336_CR70","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381(3):291\u2013293","journal-title":"N Engl J Med"},{"issue":"11","key":"5336_CR71","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard-2022-222405","volume":"81","author":"AR Balanescu","year":"2022","unstructured":"Balanescu AR, Citera G, Pascual-Ramos V et al (2022) Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis 81(11):1491\u20131503","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"5336_CR72","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291(19):2367\u20132375","journal-title":"JAMA"},{"key":"5336_CR73","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","volume":"154","author":"JA Huapaya","year":"2019","unstructured":"Huapaya JA, Hallowell R, Silhan L et al (2019) Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease. Res Med 154:6\u201311","journal-title":"Res Med"},{"issue":"2","key":"5336_CR74","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1378\/chest.11-0492","volume":"140","author":"E Diot","year":"2011","unstructured":"Diot E, Carmier D, Marquette D, Marchand-Adam S, Diot P, Lesire V (2011) IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest 140(2):562\u2013563","journal-title":"Chest"},{"issue":"2","key":"5336_CR75","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1378\/chest.10-0360","volume":"139","author":"CJ Bakewell","year":"2011","unstructured":"Bakewell CJ, Raghu G (2011) Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 139(2):441\u2013443","journal-title":"Chest"},{"issue":"3","key":"5336_CR76","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","volume":"187","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Hayakawa H, Miwa S et al (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis. Lung 187(3):201\u2013206","journal-title":"Lung"},{"key":"5336_CR77","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z (2018) Adverse effects of immunoglobulin therapy. Front Immunol 9:1299","journal-title":"Front Immunol"},{"key":"5336_CR78","doi-asserted-by":"publisher","first-page":"151959","DOI":"10.1016\/j.semarthrit.2022.151959","volume":"53","author":"M McPherson","year":"2022","unstructured":"McPherson M, Economidou S, Liampas A, Zis P, Parperis K (2022) Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum 53:151959","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"5336_CR79","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/1346-8138.15274","volume":"47","author":"KM Matsuda","year":"2020","unstructured":"Matsuda KM, Yoshizaki A, Kuzumi A et al (2020) Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. J Dermatol 47(5):483\u2013489","journal-title":"J Dermatol"},{"issue":"Suppl 1","key":"5336_CR80","first-page":"9","volume":"9","author":"H Kawasumi","year":"2015","unstructured":"Kawasumi H, Gono T, Kawaguchi Y, Yamanaka H (2015) Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circulat Res Pulmon Med 9(Suppl 1):9\u201317","journal-title":"Clin Med Insights Circulat Res Pulmon Med"},{"issue":"1","key":"5336_CR81","first-page":"87","volume":"5","author":"N Sasaki","year":"2021","unstructured":"Sasaki N, Ishii A, Kurabayashi T et al (2021) Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease. Modern Rheum Case Rep 5(1):87\u201394","journal-title":"Modern Rheum Case Rep"},{"issue":"4","key":"5336_CR82","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","volume":"59","author":"Y Abe","year":"2020","unstructured":"Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N (2020) Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford) 59(4):767\u2013771","journal-title":"Rheumatology (Oxford)"},{"key":"5336_CR83","doi-asserted-by":"publisher","first-page":"750275","DOI":"10.1155\/2013\/750275","volume":"2013","author":"O Sasaki","year":"2013","unstructured":"Sasaki O, Dohi M, Harada H et al (2013) A case of polymyxin b-immobilized fiber column treatment for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis. Case Rep Med 2013:750275","journal-title":"Case Rep Med"},{"key":"5336_CR84","first-page":"51","volume":"20","author":"H Ichiyasu","year":"2017","unstructured":"Ichiyasu H, Sakamoto Y, Yoshida C et al (2017) Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. Res Med Case Rep 20:51\u201354","journal-title":"Res Med Case Rep"},{"issue":"7","key":"5336_CR85","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1753465817708950","volume":"11","author":"H Ichiyasu","year":"2017","unstructured":"Ichiyasu H, Horio Y, Masunaga A et al (2017) Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies. Ther Adv Respir Dis 11(7):261\u2013275","journal-title":"Ther Adv Respir Dis"},{"issue":"5","key":"5336_CR86","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1164\/rccm.201508-1701OC","volume":"193","author":"FC Trudzinski","year":"2015","unstructured":"Trudzinski FC, Kaestner F, Sch\u00e4fers H-J et al (2015) Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure. Am J Respir Crit Care Med 193(5):527\u2013533","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"5336_CR87","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E et al (2020) Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50(4):776\u2013790","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"5336_CR88","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.healun.2021.07.014","volume":"40","author":"MM Crespo","year":"2021","unstructured":"Crespo MM, Lease ED, Sole A et al (2021) ISHLT consensus document on lung transplantation in patients with connective tissue disease: part I: epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. J Heart Lung Trans 40(11):1251\u20131266","journal-title":"J Heart Lung Trans"},{"issue":"12","key":"5336_CR89","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1111\/ajt.17177","volume":"22","author":"A Rivi\u00e8re","year":"2022","unstructured":"Rivi\u00e8re A, Picard C, Berastegui C et al (2022) Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: a cohort study. Am J Transplant 22(12):2990\u20133001","journal-title":"Am J Transplant"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05336-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05336-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05336-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:12:10Z","timestamp":1684163530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05336-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":89,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["5336"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05336-z","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"12 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest, nor do they have anything to disclose. All co-authors take full responsibility for the integrity and accuracy of all aspects of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}